Print Page | Contact Us | Sign In | Join GSPO Today!
News & Press: Hot Topics

Preliminary Report of Remdesivir Trial Shows Improved Recovery Time in Severe COVID-19

Thursday, May 28, 2020  
Share |

Preliminary data from the Adaptive Covid-19 Treatment Trial (ACTT-1), which incorporated sites in 10 countries and evaluated the safety and efficacy of intravenous (IV) remdesivir, showed promising results for a 10-day course of remdesivir in shortening recovery time in adults hospitalized with coronavirus disease 2019 (COVID-19) and demonstrating evidence of lower respiratory tract infection.1      READ MORE